AML Derived Induced Pluripotent Stem Cells Reveal a Genotype-Independent Effect of Monocytic Differentiation in Mediating Venetoclax Resistance. Read more about AML Derived Induced Pluripotent Stem Cells Reveal a Genotype-Independent Effect of Monocytic Differentiation in Mediating Venetoclax Resistance.
Identification of High-Efficiency ß-Catenin Protein Degradation As Critical Vulnerability in B-Cell Malignancies. Read more about Identification of High-Efficiency ß-Catenin Protein Degradation As Critical Vulnerability in B-Cell Malignancies.
Trial in Progress - Alliance A051901 - Phase I Trial of Methotrexate, Rituximab, Lenalidomide, and Nivolumab (Nivo-MR2) Induction Followed By Lenalidomide and Nivolumab Maintenance in Primary Central Nervous System Lymphoma (PCNSL). Read more about Trial in Progress - Alliance A051901 - Phase I Trial of Methotrexate, Rituximab, Lenalidomide, and Nivolumab (Nivo-MR2) Induction Followed By Lenalidomide and Nivolumab Maintenance in Primary Central Nervous System Lymphoma (PCNSL).
Thirdhand Smoke As a Risk Factor for Pediatric Lymphoblastic Leukemia: Accelerated Leukemia in Female Pax5-P80R Mice. Read more about Thirdhand Smoke As a Risk Factor for Pediatric Lymphoblastic Leukemia: Accelerated Leukemia in Female Pax5-P80R Mice.
Trial in Progress: Update on the TACL T2020-003 Randomized Phase 2 Trial to Improve Diet and Exercise in Acute Lymphoblastic Leukemia (IDEAL-2). Read more about Trial in Progress: Update on the TACL T2020-003 Randomized Phase 2 Trial to Improve Diet and Exercise in Acute Lymphoblastic Leukemia (IDEAL-2).
Retrospective Cohort Analysis of Response and Survival of Children, Adolescents, and Young Adults (CAYA) with Relapsed and/or Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoma (T-LL) Treated with Curative Intent: A TACL Consortium Read more about Retrospective Cohort Analysis of Response and Survival of Children, Adolescents, and Young Adults (CAYA) with Relapsed and/or Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoma (T-LL) Treated with Curative Intent: A TACL Consortium
Immunoglobulin Sequencing Biologically Distinguishes B-Lymphoblastic Lymphoma from Acute Lymphoblastic Leukemia and Reveals a Spectrum of Disease Dissemination across Clinical Stages. Read more about Immunoglobulin Sequencing Biologically Distinguishes B-Lymphoblastic Lymphoma from Acute Lymphoblastic Leukemia and Reveals a Spectrum of Disease Dissemination across Clinical Stages.
Application of Bone Mineral Density Study Guidelines across California Pediatric Oncology Survivorship Programs. Read more about Application of Bone Mineral Density Study Guidelines across California Pediatric Oncology Survivorship Programs.
CDK8 Inhibition Represses Monocyte-like Gene Expression in Acute Myeloid Leukemia Cells and Antagonizes In Vivo Resistance to FLT3 Inhibition. Read more about CDK8 Inhibition Represses Monocyte-like Gene Expression in Acute Myeloid Leukemia Cells and Antagonizes In Vivo Resistance to FLT3 Inhibition.
Toll-like Receptor 7/8 Pathway Is a Therapeutic Target in Primary CNS Lymphoma. Read more about Toll-like Receptor 7/8 Pathway Is a Therapeutic Target in Primary CNS Lymphoma.
